Steve Krognes is currently the CEO of Pliant Therapeutics, Inc. Since taking on this role in June 2024, he has been involved in pioneering work in the field of pharmaceuticals, focusing on novel treatments that could change lives. Before this,...

Steve Krognes is currently the CEO of Pliant Therapeutics, Inc. Since taking on this role in June 2024, he has been involved in pioneering work in the field of pharmaceuticals, focusing on novel treatments that could change lives. Before this, he was the Chief Financial Officer at Denali Therapeutics from January 2021 until May 2022. During his time at Denali, Krognes played a key role in the company’s financial operations, along with facilitating its growth and development. His compensation saw a massive peak in 2021, where his total earnings reached $1.84 million, largely due to a hefty bonus and stock grants. Interestingly, Krognes transitioned to a non-employee director role recently, which meant stepping away from a sizable salary of $501,150 to $173,750 annually—showing his commitment to the company’s long-term vision over immediate personal financial gain. In addition, he serves on the Audit Committee at Pliant, showcasing his financial expertise in overseeing company audits. Steve's journey reflects a trend in leadership that values long-term goals.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

P

Steve Krognes

CEO of Pliant Therapeutics

Sector of Economy

Healthcare

CEO of Pliant Therapeutics for

0 years 11 months (Jun 2024 - Present)

Previous Experience

Experienced in corporate governance and audit

Rivals

Competitors/colleagues of Steve Krognes

Holdings

See how much did Steve Krognes make over time.

Steve Krognes has held significant stock options in Denali Therapeutics, where at one point he had options for 125,000 shares at a strike price of $5.28, set to expire in 2027. After transitioning to Pliant Therapeutics, Krognes forfeited all stock...

Steve Krognes has held significant stock options in Denali Therapeutics, where at one point he had options for 125,000 shares at a strike price of $5.28, set to expire in 2027. After transitioning to Pliant Therapeutics, Krognes forfeited all stock awards granted during his time as CFO of Denali, which reflects the shifting landscape of executive compensation where previous awards are often linked to employment status. At Pliant, he now holds options that will become available based on the company’s performance over time. Krognes' involvement in insider trading has been limited, which may suggest a cautious approach to managing his stock holdings, aiming to align with the performance of the company and its broader goals.

Total Stock Sold

$13.64M

DNLI

$13.64M

305,288 DNLI shares

What if they kept their stock?

If Steve Krognes didn't sell their stock, today they would have:
Extra DNLI305,288 shares worth $8.24M.
This is -39.59% and $5.40M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Steve Krognes.

DNLI

$41.09K

DNLI at $23.79/share

Aug 20, 2024

Sale

DNLI

$682.40K

DNLI at $22.24/share

Jun 13, 2024

Sale

DNLI

5,967 shares

DNLI

May 31, 2024

Received

DNLI

$1.90M

DNLI at $20.50/share

Apr 1, 2024

Sale

DNLI

$47.55K

DNLI at $17.29/share

Feb 13, 2024

Sale

DNLI

$62.33K

DNLI at $19.43/share

Jan 5, 2024

Sale

DNLI

$32.07K

DNLI at $22.60/share

Aug 21, 2023

Sale

DNLI

4,216 shares

DNLI

Jun 1, 2023

Received

DNLI

$63.78K

DNLI at $30.10/share

Feb 13, 2023

Sale

DNLI

$42.52K

DNLI at $30.88/share

Feb 8, 2023

Sale

Compensation History

See how much did Steve Krognes make over time.

In 2022, Steve Krognes earned a base salary of $173,750 at Pliant Therapeutics, a significant drop from his previous role where he earned over $1.84 million in 2021 at Denali Therapeutics. His last year at Denali included a hefty bonus of $300,690, which was due to the achievement of corporate goals. However, in 2022, Krognes did not receive a bonus because he transitioned to a board director role, demonstrating how his focus has shifted from salary to governance and directing the company's long-term strategy. He also received $6,683 in additional contributions, reflecting the standard employer benefits such as 401(k) matching. This shift indicates how Krognes may now prioritize the stability and performance of Pliant over immediate compensation.

Year

2022

Total Compensation

$173.75K

Salary

$167.07K

Board Justification

The compensation philosophy focuses on pay for performance and alignment with stockholder interests.

Bonus

$0.00

Board Justification

No annual bonus was earned for 2022 due to transition to non-employee director role.

Other

$6.68K

Board Justification

This includes employer 401(k) matching contributions paid to Mr. Krognes.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock awards vested in 2022 as all stock and option awards granted during the year were forfeited upon transition.

Performance Metrics

Performance metrics for bonuses were based on achievement of corporate goals, but no bonus was earned due to transition.